CORDIS
EU research results

CORDIS

English EN

Next generation sepsis diagnosis

Objective

Sepsis is a potentially fatal condition that arises when the body’s response to an infection damages its own tissues and organs. It is mainly caused by bacteria and fungi, which spread through the blood circulation. It is one of the biggest public health issue in the EU and worldwide due to its high incidence, mortality, human and economic cost. Early diagnosis is crucial to the management of sepsis, as every hour of delay of appropriate antibiotic therapy increases mortality by 5-10%.
Unfortunately, sepsis diagnosis remains one of the greatest clinical challenges in critical care. Current diagnostic methods, including blood culture and different nucleic acid based multiplex technologies, are impaired by the significant time-delay of 1-2 days and/or low sensitivity of 30-50%. Hence there is an urgent need to develop new diagnostic tools that can provide more accurate and earlier sepsis diagnosis, so that patients with sepsis can be administered with rapid and correct initial antimicrobial treatment.
The SMARTDIAGNOS project will advance sepsis diagnosis by simplifying clinical sample analysis methods and integrating the currently required numerous steps into a single streamlined device. This will be achieved by combining a number of innovative technologies: 1) 3-dimentional sample concentration to process large amount of raw sample; 2) direct PCR in the 3D microstructure to circumvent DNA extraction step; 3) solid-phase PCR to achieve unlimited multiplexing capability; 4) supercritical angle fluorescence (SAF) microlens array for enhanced fluorescence detection and precise quantification of sepsis-related pathogens.
The SMARTDIAGNOS system will go beyond the state of the art for shorter time (1-3 h), higher sensitivity (95%), higher selectivity (99%), multiplexing capability, antimicrobial resistance profiling, and automation. Fast and correct sepsis diagnosis will improve patient outcome, shorten intensive care stay and thus reduce health costs.

Coordinator

DANMARKS TEKNISKE UNIVERSITET

Address

Anker Engelundsvej 1 Bygning 101 A
2800 Kgs Lyngby

Denmark

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 393 615,95

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

COPENHAGEN BUSINESS SCHOOL

Denmark

EU Contribution

€ 122 955

TATAA BIOCENTER AB

Sweden

EU Contribution

€ 248 624,25

SCANDINAVIAN MICRO BIODEVICES APS

Denmark

EU Contribution

€ 699 953,80

CUBE DX GMBH

Austria

EU Contribution

€ 721 122,50

UNILABS AB

Sweden

EU Contribution

€ 126 250

HOGSKOLAN I SKOVDE

Sweden

EU Contribution

€ 183 500

UNIVERZITA KARLOVA

Czechia

EU Contribution

€ 130 000

UNIVERSITAT FUR WEITERBILDUNG KREMS

Austria

EU Contribution

€ 273 550

DIN DEUTSCHES INSTITUT FUER NORMUNG E.V.

Germany

EU Contribution

€ 128 337,50

Project information

Grant agreement ID: 687697

Status

Ongoing project

  • Start date

    1 February 2016

  • End date

    31 January 2020

Funded under:

H2020-EU.2.1.1.

  • Overall budget:

    € 4 797 602,09

  • EU contribution

    € 4 027 909

Coordinated by:

DANMARKS TEKNISKE UNIVERSITET

Denmark